Australian & New Zealand Childrens Haematology/Oncology Group

The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) is a non-profit organisation, committed to ensuring Australian and New Zealand children and adolescents receive world-class cancer care.

We are the peak professional body for paediatric oncologists and health professionals who care for children with cancer, spearheading national initiatives to enhance clinical care through communication, networking and education.

ANZCHOG is also the national cooperative clinical trials group for childhood cancer, actively working with trial consortia around the world to ensure Australian and New Zealand children have the opportunity to access the latest promising cancer treatments.


What we're doing

We are committed to ensuring that all Australian and New Zealand children with cancer have equitable access to state of the art care. We do this by ensuring that our members have ample opportunity to communicate, collaborate and draw upon their collective expertise to optimise the outcome of each patient.

The past and future successes of the global paediatric oncology community have been and will be built on the cornerstone of clinical trials. ANZCHOG plays a pivotal role in providing national coordination of this clinical trial research agenda, both by fostering our own members’ research and also by collaborating with a range of national and international organisations to ensure our patients can participate in world leading research.

Learn More

COVID-19 Vaccination Guidance

For children 5 years and older undergoing cancer treatment and children with non-cancerous blood disorders

Learn more


Contact us to find out how you can donate and help ANZCHOG bring the latest clinical trials to Australia and New Zealand!

Donate Here

News & events


This year’s ASM will run from 1 – 3 August and submissions for abstracts are now open. It’s all happening in Adelaide (Tarntanya) this year, with the theme, “Sparking hope through cutting edge technologies and collaborative care. Tangka parranthi.”.

Read more
Position Statement – Eflornithine (DFMO) use for patients with high-risk neuroblastoma in Australia and New Zealand

The ANZCHOG Solid Tumour Group has developed an endorsed position statement on the use of Eflornithine (DFMO) for patients with high-risk neuroblastoma in Australia and New Zealand.

Read more
A promising advancement for New Zealand children and adolescents with cancer

In positive news for New Zealand children and adolescents with cancer, the ZERO2 clinical study has opened at Starship Children’s Hospital, Auckland.

Read more

Our supporters & partners

We rely on the generosity of the community and government to improve the care and treatment of children with cancer. That support, combined with partnerships here and overseas, are vital to our ongoing research and education projects.

Learn More